.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Fuji
Chubb
Express Scripts
Queensland Health
Teva
Cipla
Merck
Argus Health

Generated: December 16, 2017

DrugPatentWatch Database Preview

Schering Company Profile

« Back to Dashboard

What is the competitive landscape for SCHERING, and what generic alternatives to SCHERING drugs are available?

SCHERING has one hundred and two approved drugs.

There are nine US patents protecting SCHERING drugs on SCHERING drugs in the past three years.

There are eighty-three patent family members on SCHERING drugs in thirty-two countries and forty-five supplementary protection certificates in ten countries.

Summary for Schering

International Patents:83
US Patents:9
Tradenames:64
Ingredients:56
NDAs:102
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
ScheringPROVENTILalbuterol sulfateTABLET;ORAL017853-002May 7, 1982DISCNYesNo► Subscribe► Subscribe► Subscribe
ScheringTHEO-DURtheophyllineCAPSULE, EXTENDED RELEASE;ORAL087995-001Sep 10, 1985DISCNNoNo► Subscribe► Subscribe► Subscribe
ScheringNAQUAtrichlormethiazideTABLET;ORAL012265-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
ScheringTHEOVENTtheophyllineCAPSULE, EXTENDED RELEASE;ORAL087010-001Jan 31, 1985DISCNNoNo► Subscribe► Subscribe► Subscribe
ScheringTHEO-DURtheophyllineCAPSULE, EXTENDED RELEASE;ORAL088016-001Sep 10, 1985DISCNNoNo► Subscribe► Subscribe► Subscribe
ScheringPROVENTILalbuterol sulfateSOLUTION;INHALATION019243-001Jan 14, 1987DISCNNoNo► Subscribe► Subscribe► Subscribe
ScheringTHEO-DURtheophyllineCAPSULE, EXTENDED RELEASE;ORAL088015-001Sep 10, 1985DISCNNoNo► Subscribe► Subscribe► Subscribe
ScheringDIPROSONEbetamethasone dipropionateLOTION;TOPICAL017781-001Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe► Subscribe
ScheringTHEOVENTtheophyllineCAPSULE, EXTENDED RELEASE;ORAL087910-001Jan 31, 1985DISCNNoNo► Subscribe► Subscribe► Subscribe
ScheringTHEO-DURtheophyllineCAPSULE, EXTENDED RELEASE;ORAL088022-001Sep 10, 1985DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Schering

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
ScheringINTEGRILINeptifibatideINJECTABLE;INJECTION020718-001May 18, 1998► Subscribe► Subscribe
ScheringINTEGRILINeptifibatideINJECTABLE;INJECTION020718-001May 18, 1998► Subscribe► Subscribe
ScheringPROVENTILalbuterol sulfateTABLET, EXTENDED RELEASE;ORAL019383-001Jul 13, 1987► Subscribe► Subscribe
ScheringVANCENASEbeclomethasone dipropionateAEROSOL, METERED;NASAL018521-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
ScheringNORMOZIDEhydrochlorothiazide; labetalol hydrochlorideTABLET;ORAL019046-003Apr 6, 1987► Subscribe► Subscribe
ScheringINTEGRILINeptifibatideINJECTABLE;INJECTION020718-001May 18, 1998► Subscribe► Subscribe
ScheringPROVENTILalbuterol sulfateTABLET;ORAL017853-001May 7, 1982► Subscribe► Subscribe
ScheringRENORMAXspirapril hydrochlorideTABLET;ORAL020240-004Dec 29, 1994► Subscribe► Subscribe
Schering PloughLOTRIMINclotrimazoleSOLUTION;TOPICAL017613-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
ScheringPROVENTILalbuterol sulfateSOLUTION;INHALATION019243-001Jan 14, 1987► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for SCHERING drugs

Drugname Dosage Strength Tradename Submissiondate
posaconazoleInjection18 mg/mL, 16.7 mL vialsNOXAFIL11/24/2015
posaconazoleDelayed-release Tablets100 mgNOXAFIL6/16/2014
posaconazoleOral Suspension40 mg/mLNOXAFIL2/28/2011
eptifibatideInjection0.75 mg/mL, 100 mL vialINTEGRILIN6/5/2009
eptifibatideInjection2 mg/mL, 100 mL vialINTEGRILIN12/18/2008
eptifibatideInjection2 mg/mL, 10 mL vialINTEGRILIN9/30/2008

Non-Orange Book Patents for Schering

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,693,626 Tetrahydrofuran antifungals► Subscribe
6,713,481 Crystalline antifungal polymorph► Subscribe
5,710,154 Tetrahydrofuran antifungals► Subscribe
5,714,490 Tetrahydrofuran antifungals► Subscribe
5,703,236 Tetrahydrofuran antifungals► Subscribe
5,703,079 Tetrahydrofuran antifungals► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Schering Drugs

Country Document Number Estimated Expiration
Germany69428125► Subscribe
South Africa200307684► Subscribe
Germany69628117► Subscribe
European Patent Office0736030► Subscribe
Australia1512795► Subscribe
Finland962577► Subscribe
Poland181193► Subscribe
Japan4308902► Subscribe
Japan2008120836► Subscribe
China1161038► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Schering Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2011 00026Denmark► SubscribePRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216
C0004France► SubscribePRODUCT NAME: DESLORATADINE; PSEUDOEPHEDRINE SULFATE; REGISTRATION NO/DATE: EU/1/07/399/001 20070730
00095Netherlands► SubscribePRODCUT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH VERDRAAGBAAR ZOUT, EN HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/02/213/001-010 20020419
C/GB02/037United Kingdom► SubscribePRODUCT NAME: TELMISARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/02/213/001 20020419; UK EU/1/02/213/002 20020419; UK EU/1/02/213/003 20020419; UK EU/1/02/214/004 20020419; UK EU/1/02/213/005 20020419; UK EU/1/02/213/006 20020419; UK EU/1/02/213/007 20020419; UK EU/1/02/213/008 20020419; UK EU/1/02/213/009 20020419; UK EU/1/02/213/010 20020419
13/055Ireland► SubscribePRODUCT NAME: THE COMBINATION OF: (A) DEXTROMETHORPHAN OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. DEXTROMETHORPHAN HYDROBROMIDE AND IN PARTICULAR DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE; AND (B) QUINIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. QUINIDINE SULPHATE AND IN PARTICULAR QUINIDINE SULPHATE DIHYDRATE, PROTECTED BY THE BASIC PATENT; REGISTRATION NO/DATE: EU/1/13/833 20130624
C/GB08/005United Kingdom► SubscribeSUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022.
00221Netherlands► SubscribePRODUCT NAME: DROSPIRENON EN ETHINYLESTRADIOL; REGISTRATION NO/DATE: RVG 23827 20000307
C0055France► SubscribePRODUCT NAME: SULFATE DE SODIUM ANHYDRE, SULFATE DE MAGNESIUM HEPTAHYDRATE, SULFATE DE POTASSIUM; NAT. REGISTRATION NO/DATE: NL41696 20130426; FIRST REGISTRATION: 434323 20130220
C/GB95/010United Kingdom► SubscribePRODUCT NAME: 2-N-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL) METHYL) -5-(HYDROXYMETHYL) IMIDAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT; REGISTERED: SE 12209 19940902; UK 0025/0324 19941215; UK 0025/0336 19941215
C0025Belgium► SubscribePRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Medtronic
QuintilesIMS
Federal Trade Commission
Chubb
Harvard Business School
Boehringer Ingelheim
Dow
US Department of Justice
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot